4.7 Article

High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer

期刊

CANCER LETTERS
卷 514, 期 -, 页码 79-89

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.05.011

关键词

RHAMM; Pancreatic ductal adenocarcinoma; Pancreatic neuroendocrine tumor; Mouse models; p53

类别

资金

  1. NIH [R01CA204916-01A1]
  2. DoD [W81XWH-16-1-0619]
  3. Center for Translational Pathology at the Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
  4. STARR [I12-0043]

向作者/读者索取更多资源

Pancreatic cancer has the lowest survival rate and urgent need for better treatment; RHAMM is a potential therapeutic target for pancreatic cancer; HMMRAexon8-16 lacking centrosome targeting domain accelerates cancer progression.
Pancreatic cancer has the lowest survival rate out of all types of cancer. Pancreatic cancer patients are often diagnosed at advanced stages, hence an urgent need for a better therapeutic development of this devastating disease. Receptor for hyaluronan-mediated motility (RHAMM), not expressed in adult normal pancreas, has been suggested as a prognostic factor and a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (PNET). In this study, we initially sought to determine whether genetic deletion of RHAMM would slow down pancreatic cancer progression using Rhamm- /- mice. However, we found that Rhamm-/- mice expressed a truncated HMMRAexon8-16 protein at higher abundance levels than wild-type RHAMM. While HMMRAexon8-16 did not enable malignant progression of pancreatic intraepithelial neoplasia in p48-Cre; LSL-KRASG12D mice, it accelerated the formation of invasive PDAC and shortened the survival of p48Cre; LSL-KRASG12D mice with heterozygous p53 knockout. KrasG12D PDAC mice with homozygous p53 knockout mice died around 10 weeks, and the effect of HMMRAexon8-16 was not apparent in these short lifespan mice. In addition, HMMRAexon8-16 shortened the survival of PNET-bearing RIP-Tag mice, which had inactivated p53. In our analysis of TCGA dataset, pancreatic cancer patients with mutant TP53 or loss of one copy of TP53 had higher RHAMM expression, which, combined, predicted worse outcomes. Taken together, by collaborating with dysfunctional p53, high levels of HMMRAexon8-16 , which lacks the centrosome targeting domain and degrons for interaction with the Anaphase-Promoting Complex (APC), accelerated pancreatic cancer progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据